Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
22.78
+2.27 (11.07%)
At close: Oct 6, 2025, 4:00 PM EDT
21.95
-0.83 (-3.64%)
Pre-market: Oct 7, 2025, 4:38 AM EDT
Nanobiotix Employees
Nanobiotix had 108 employees as of December 31, 2024. The number of employees increased by 6 or 5.88% compared to the previous year.
Employees
108
Change (1Y)
6
Growth (1Y)
5.88%
Revenue / Employee
$110,470
Profits / Employee
-$561,569
Market Cap
1.05B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 108 | 6 | 5.88% |
| Dec 31, 2023 | 102 | 0 | - |
| Dec 31, 2022 | 102 | 2 | 2.00% |
| Dec 31, 2021 | 100 | 10 | 11.11% |
| Dec 31, 2020 | 90 | -20 | -18.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NBTX News
- 4 days ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 5 days ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 6 days ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire
- 7 days ago - NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC - GlobeNewsWire
- 18 days ago - Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday - Benzinga
- 18 days ago - Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case - Seeking Alpha
- 18 days ago - Nanobiotix S.A. - Special Call - Seeking Alpha
- 19 days ago - NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1 - GlobeNewsWire